Certain protocols for administering gadolinium-based contrast agents can eliminate new cases of nephrogenic systemic fibrosis, a new study shows.

According to a retrospective review of 52,954 contrast-enhanced MRIs at Massachusetts General Hospital, implementing strict protocols can prevent the development of nephrogenic systemic fibrosis. Dr. Ozden Narin, presenting author of the study said implementing these protocols is particularly important in the case of patients with diminished kidney function.

"In the past, we had some patients who developed NSF after they were given a gadolinium-based agent before imaging." Narin said. "We implemented this new policy to see if we could make any change in preventing this condition. Now we only use Gadolinium-based contrast agents in patients with decreased kidney function in emergent cases and we have procedures in place to pay special attention to those patients and to take all the necessary precautions."

If you have developed nephrogenic systemic fibrosis after being administered a gadolinium-based contrast agent, please contact the gadolinium injury attorneys of Williams Kherkher by calling 800-761-3187.